Our Firm is representing numerous women who were allegedly harmed by pelvic implants manufactured by C.R. Bard, Ethicon and other companies.
New York, NY (PRWEB) January 11, 2015
Transvaginal mesh lawsuits (http://www.transvaginalmeshlawsuithelp.com/) against Ethicon and C.R. Bard Inc. are moving forward in New Jersey Superior Court, where two state litigations have scheduled their February status conferences, Bernstein Liebhard LLP reports.
A Calendar posted on the Court’s website indicates that Case Management Conferences in two separate proceedings will take place on February 5, 2015. The C.R. Bard litigation will meet at 10:30 a.m. on that day, while parties involved in claims that allege injuries caused by Ethicon’s line of Gynecare implants will convene at 1:30 p.m. The status conferences will take place in Bergen County Superior Court, where thousands of transvaginal mesh lawsuits continue to be filed. (In re: Pelvic Mesh Litigation/Bard, No. L-6339-10; In re: Pelvic Mesh/Gynecare Litigation, No. 6341-10)
“We are pleased to see further progress in the New Jersey transvaginal mesh litigations, as our Firm is representing numerous women who were allegedly harmed by pelvic implants manufactured by C.R. Bard, Ethicon and other companies,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices including transvaginal mesh. The Firm is currently offering free and confidential case evaluations to women who allege mesh erosion, chronic pain, pain during sexual intercourse and other complications resulting from products manufactured by C.R. Bard, Ethicon, American Medical Systems, and Boston Scientific Corp.
Transvaginal Mesh Lawsuits
Transvaginal mesh lawsuits now pending in the C.R. Bard and Ethicon litigations in Bergen County were filed after a 2008 health alert from the U.S. Food and Drug Administration (FDA) that warned about the risk of vaginal mesh complications stemming from use of the pelvic implants. At this time, the FDA stated that the potential for these problems to occur was “rare.” The FDA upstaged its stance three years later to indicate that the risk for issues to stem from use of these products was “not rare.” The July 2011 notice was issued after the federal regulator received 3,000 adverse event reports from women who alleged instances of mesh erosion and other complications caused by transvaginal mesh.
In April 2014, the FDA took its most recent step by proposing new regulations that would classify the devices as “high risk,” requiring that manufacturers submit them for rigorous testing for safety prior to receiving market clearance.*
Jeffrey S. Grand, a partner at Bernstein Liebhard LLP, is actively serving as Co-Liaison Counsel for the consolidated New Jersey litigation involving C.R. Bard mesh, as well as the one established for Ethicon-related claims. For this proceeding, Mr. Grand was on the Plaintiff’s trial team for a trial that concluded in March 2013 with an $11 million verdict in favor of a woman who received a Gynecare Prolift implant.
Mr. Grand is also serving on the Plaintiffs’ Steering Committees in a number of federal multidistrict mesh litigations underway in the U.S. District Court, Southern District of West Virginia. Together, they the following proceedings include more than 60,000 transvaginal mesh suits: (In Re: C.R. Bard, Inc., Pelvic Repair System Products Liability Litigation - MDL No. 2187; In Re: American Medical Systems, Inc., Pelvic Repair Systems Products Liability Litigation - MDL No. 2325; In Re: Boston Scientific Corp., Pelvic Repair Systems Products Liability Litigation - MDL No. 2326; In re: Ethicon, Inc. Pelvic Repair Systems Products Liability Litigation - MDL No. 2327; Coloplast Corp. Pelvic Support Systems Products Liability Litigation - MDL No. 2387; In Re: Cook Medical, Inc., Pelvic Repair System Products Liability Litigation - MDL No. 2440; and In Re: Neomedic Pelvic Repair System Products Liability Litigation - MDL No. 2511.)
Women who allege serious complications of transvaginal mesh may be entitled to receive compensation for lost wages, medical bills, pain and suffering, as well as other injury-related damages. Learn more about filing a transvaginal mesh lawsuit by visiting Bernstein Liebhard LLP’s website, or via the Firm’s Facebook page: https://www.facebook.com/meshlawsuit. To obtain a free, confidential and no-obligation case review, please call 800-511-5092.
*http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm395192.htm, U.S. Food and Drug Administration (FDA), April 29, 2014.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP